adenovirus
ad
possess
sever
attribut
make
suitabl
candid
vaccin
vector
ad
exert
adjuvantlik
effect
stimul
innat
immun
system
tolllik
receptor
tlr
depend
tlrindepend
pathway
effect
ad
vectorbas
vaccin
mani
infecti
diseas
includ
measl
sever
acut
respiratori
syndrom
sar
human
immunodefici
viru
hiv
hepat
b
ebola
evalu
anim
model
clinic
trial
human
previous
other
explor
potenti
human
ad
serotyp
vectorbas
vaccin
strategi
influenza
immunogen
protect
efficaci
studi
demonstr
ad
vectorbas
vaccin
provid
complet
protect
challeng
homolog
antigen
distinct
strain
influenza
virus
mous
model
high
incid
ad
infect
gener
popul
due
circul
fifti
ad
serotyp
ubiquit
natur
result
develop
adspecif
neutral
antibodi
popularli
known
preexist
vector
immun
major
individu
adneutr
antibodi
inhibit
vector
extracellularli
adspecif
cell
destroy
vector
express
cell
therebi
advers
impact
durat
level
transgen
express
experiment
studi
anim
model
shown
presenc
extrem
high
level
adneutr
antibodi
signific
inhibit
develop
immunogenspecif
immun
respons
comprehens
analysi
ad
seropreval
found
neutral
antibodi
titer
studi
particip
vari
geograph
locat
rang
accord
studi
particip
titer
titer
exhibit
titer
greater
studi
underscor
need
evalu
role
vector
immun
inhibit
immunogen
efficaci
vectorbas
vaccin
determin
level
vector
immun
toler
without
significantli
affect
vaccin
efficaci
prime
group
mice
vari
dose
wild
type
wt
via
intranas
intramuscular
im
rout
inocul
gener
differ
level
antibodi
titer
develop
immun
hadprim
mice
immun
im
low
high
dose
vector
hadhanp
carri
hemagglutinin
ha
nucleoprotein
np
gene
influenza
viru
also
assess
could
overcom
vector
immun
increas
vaccin
dose
chang
rout
immun
result
suggest
high
level
neutral
titer
vector
immun
toler
effect
overcom
increas
vaccin
dose
use
altern
rout
vaccin
full
code
region
ha
control
cytomegaloviru
cmv
immedi
earli
promot
bovin
growth
hormon
bgh
polyadenyl
signal
polya
full
length
code
region
np
gene
viru
control
murin
cmv
promot
simian
viru
polya
insert
earli
region
genom
use
crerecombinasemedi
sitespecif
recombin
system
gene
hadhanp
orient
recombin
vector
hadhanp
figur
show
visibl
cytopath
effect
cpe
ninth
day
posttransfect
western
blot
analysi
done
confirm
express
ha
np
cell
two
distinct
polypeptid
band
approxim
molecular
weight
kda
kda
repres
ha
precursor
proteolyt
cleavag
product
respect
figur
observ
hadhanp
infect
cell
lysat
singl
band
approxim
molecular
weight
kda
repres
np
figur
visibl
hadhanp
infect
cell
lysat
mimic
mous
model
preexist
immun
observ
major
human
popul
group
anim
inocul
im
singl
dose
plaqu
form
unit
pfu
hadwt
im
prime
group
show
dosedepend
increas
level
hadspecif
neutral
antibodi
titer
figur
expect
highest
hadspecif
neutral
antibodi
titer
inocul
hadprim
group
observ
pfu
dose
hadwt
follow
pfu
pfu
dose
figur
similarli
im
prime
group
receiv
pfu
hadwt
develop
highest
titer
follow
pfu
pfu
dose
group
fig
im
prime
group
result
develop
higher
level
hadspecif
neutral
antibodi
titer
compar
prime
group
develop
robust
haspecif
antibodi
respons
import
indic
immunogen
protect
efficaci
influenza
vaccin
im
immun
anim
hadhanp
elicit
dosedepend
geometr
mean
gm
hemagglutin
inhibit
hi
titer
tabl
hadprim
group
develop
significantli
high
serum
hi
titer
compar
vector
control
group
im
rout
immun
pfu
hadhanp
similarli
im
prime
group
develop
significantli
higher
serum
hi
titer
compar
vector
control
group
im
rout
immun
hadhanp
serum
hi
titer
hadprim
group
im
immun
vaccin
fold
lower
immun
group
indic
hadpreexist
antibodi
affect
induct
humor
immun
respons
follow
immun
hadhanp
hadprim
group
immun
hadhanp
induc
lower
serum
hi
titer
compar
group
immun
im
hadhanp
interestingli
increas
vaccin
dose
fivefold
result
signific
enhanc
serum
hi
titer
mice
immun
either
im
similar
trend
observ
case
im
hadprim
group
indic
altern
rout
prime
immun
increas
vaccin
dose
partial
overcom
vector
immun
hadprim
group
immun
hadhanp
induc
lower
serum
hi
titer
altern
im
rout
immun
result
slight
improv
hi
titer
increas
vaccin
dose
fivefold
result
improv
hi
titer
mice
immun
either
im
indic
ininduc
mimic
natur
rout
infect
human
vector
immun
partial
overcom
increas
vaccin
dose
howev
im
hadprim
group
immun
hadhanp
hi
titer
induc
signific
chang
titer
either
altern
rout
vaccin
inocul
increas
vaccin
dose
result
indic
level
vector
immun
induc
im
prime
pfu
neg
impact
develop
humor
immun
respons
vectorbas
vaccin
cellmedi
immun
cmi
play
import
role
viru
clearanc
thu
contribut
recoveri
influenza
infect
anticip
hadhanp
vaccin
elicit
significantli
higher
percentag
epitopespecif
cell
group
compar
vector
control
group
figur
percentag
epitopespecif
cell
hadprim
group
im
significantli
higher
vector
control
group
follow
immun
hadhanp
either
im
rout
howev
percentag
cell
fold
lower
hadprim
group
im
compar
group
suggest
preexist
vector
immun
modest
effect
induct
cmi
follow
immun
hadhanp
figur
percentag
epitopespecif
cell
hadprim
group
twofold
lower
compar
hadprim
group
im
follow
immun
hadhanp
either
rout
figur
interestingli
increas
vaccin
dose
fivefold
result
significantli
higher
percentag
epitopespecif
cell
hadprim
group
compar
hadprim
group
receiv
lower
dose
pfu
vaccin
expect
increas
level
preexist
vector
immun
led
decreas
percentag
epitopespecif
cell
furthermor
increas
vaccin
dose
fivefold
result
significantli
higher
percentag
epitopespecif
cell
prime
group
compar
prime
group
receiv
lower
vaccin
dose
pfu
howev
increas
notic
im
prime
group
function
cell
assess
enumer
express
cell
elispot
assay
significantli
higher
number
cell
detect
spleen
group
immun
im
hadhanp
compar
vector
control
group
follow
stimul
peptid
respect
figur
gener
number
cell
spleen
hadprim
group
immun
vaccin
lower
compar
immun
group
fivefold
increas
vaccin
dose
result
increas
number
secret
cell
prime
group
except
im
prime
group
figur
overal
seem
increas
preexist
antibodi
titerdepend
declin
cmi
respons
significantli
improv
increas
vaccin
dose
fivefold
excel
correl
elispot
np
pentam
stain
data
unprim
mice
immun
hadhanp
lung
viral
titer
day
postchalleng
level
detect
similarli
hadprim
group
im
immun
hadhanp
lung
viral
titer
level
detect
indic
preexist
vector
immun
advers
impact
protect
efficaci
howev
hadprim
group
im
immun
hadhanp
rout
use
prime
exhibit
less
effici
viru
clearanc
lung
interestingli
either
use
differ
rout
inocul
prime
vaccin
increas
vaccin
dose
fivefold
result
lung
viral
titer
level
detect
hadprim
group
im
immun
hadhanp
rout
use
prime
partial
approxim
log
viru
clearanc
chang
rout
prime
immun
complet
protect
observ
group
prime
follow
fivefold
increas
vaccin
dose
administ
either
rout
im
even
fivefold
increas
vaccin
dose
yield
complet
protect
im
hadprim
group
immun
hadhanp
either
rout
im
suggest
level
preexist
vectorneutr
antibodi
titer
could
serv
indic
predict
efficaci
adbas
vaccin
meet
global
vaccin
demand
pandem
variou
eggindepend
vaccin
strategi
need
explor
supplement
eggdepend
influenza
vaccin
approach
ad
vectorbas
influenza
vaccin
shown
clinic
studi
safe
immunogen
human
strong
innat
adapt
immun
respons
induc
ad
vector
impart
adjuvantlik
properti
facilit
better
immun
respons
transgen
product
howev
sever
preclin
studi
suggest
presenc
preexist
hadspecif
neutral
antibodi
might
inhibit
gener
immun
respons
express
immunogen
present
studi
evalu
role
preexist
neutral
antibodi
inhibit
immunogen
efficaci
vectorbas
influenza
vaccin
mous
model
low
level
vector
immun
virusneutr
titer
seem
advers
affect
protect
vaccin
efficaci
increas
vector
immun
taken
care
use
altern
rout
immun
increas
vaccin
dose
import
npspecif
cell
nonneutr
antibodi
viru
clearanc
pursu
studi
mimic
natur
exposur
major
human
prime
mice
rout
establish
state
preexist
vector
immun
sinc
mani
infect
via
mucos
rout
im
group
repres
develop
hadspecif
immun
respons
follow
im
immun
vectorbas
vaccin
attempt
circumv
inhibitori
effect
high
level
preexist
vector
immun
either
chang
rout
vaccin
inocul
increas
vaccin
dose
presenc
preexist
neutral
antibodi
modest
declin
level
cmi
hi
level
respons
immun
hadhanp
level
immun
respons
suffici
enough
provid
excel
protect
challeng
reassort
viru
lower
level
humor
cellular
immun
respons
immun
compar
im
immun
consist
earlier
find
increas
level
vectorspecif
neutral
antibodi
respons
result
greater
declin
influenza
virusspecif
immun
respons
inhibit
pronounc
rout
inocul
adprim
influenza
viru
immun
eg
im
im
level
vector
immun
could
overcom
either
chang
rout
prime
immun
increas
vaccin
dose
fivefold
test
upper
limit
vector
immun
could
toler
without
advers
affect
vaccin
protect
efficaci
vectorspecif
neutral
antibodi
titer
rais
prime
high
dose
inhibitori
effect
partial
overcom
fivefold
increas
vaccin
dose
result
immun
respons
suffici
provid
complet
protect
increas
level
vectorspecif
neutral
antibodi
titer
im
prime
provid
partial
protect
even
group
receiv
high
vaccin
dose
altern
rout
prime
immun
partial
success
overcom
vector
immun
thu
indic
potenti
role
rout
inocul
develop
level
humor
cmi
respons
suggest
rout
vaccin
impact
magnitud
phenotyp
traffick
antigenspecif
cell
mice
hadbas
hiv
vaccin
also
show
inhibit
elicit
immunogenspecif
immun
respons
presenc
vector
immun
howev
effect
minim
increas
vaccin
dose
nevertheless
clinic
trial
hadbas
influenza
vaccin
strong
correl
vector
immun
level
decreas
vaccin
efficaci
inhibitori
effect
vector
immun
pronounc
humor
immun
respons
compar
cmi
respons
consist
previou
report
taken
togeth
data
clearli
show
magnitud
humor
cellular
immun
respons
advector
vaccin
antigen
depend
upon
level
preexist
antibodi
vector
howev
vectorspecif
immun
respons
overcom
increas
antigen
dose
administ
antigen
differ
rout
conclus
base
present
studi
alon
difficult
predict
rang
vector
immun
human
toler
overcom
either
increas
dose
chang
rout
administr
vectorbas
vaccin
nevertheless
studi
highlight
import
explor
strategi
human
improv
outcom
vectorbas
vaccin
purdu
univers
biosafeti
committe
anim
care
use
committe
approv
protocol
anim
studi
purdu
univers
auspic
institut
anim
care
use
committe
iacuc
support
american
associ
laboratori
anim
scienc
aala
cell
line
obtain
commerci
american
type
cultur
collect
atcc
cell
line
obtain
merck
co
cell
line
creat
pi
laboratori
use
combin
commerci
avail
cell
line
mdbk
use
human
cell
line
construct
hybrid
cell
line
permiss
purdu
univers
institut
review
board
irb
form
accord
feder
regul
research
exempt
obtain
use
commerci
avail
human
cell
line
irb
unit
human
research
protect
program
hrpp
hous
within
offic
research
administr
ora
human
embryon
kidney
cell
express
gene
product
obtain
atcc
cell
constitut
express
crerecombinas
enzym
gift
merck
inc
whitehous
station
nj
grown
monolay
cultur
eagl
minimum
essenti
medium
mem
life
technolog
gaithersburg
md
supplement
reconstitut
bovin
serum
fetal
clone
iii
hyclon
logan
vt
gentamycin
construct
purifi
cesium
chlorid
densitygradi
centrifug
titrat
plaqu
assay
hybrid
cell
line
use
mdbk
cell
line
describ
previous
construct
propag
replic
defect
vector
delet
region
previous
describ
viru
purifi
cesium
chlorid
densitygradi
centrifug
titrat
plaqu
assay
cell
crerecombinasemedi
sitespecif
recombin
techniqu
use
insert
fulllength
code
region
ha
gene
modifi
polybas
site
influenza
viru
control
cmv
promot
bgh
polya
polybas
cleavag
site
present
ha
gene
influenza
viru
modifi
reduc
rare
possibl
genet
exchang
ha
hadhanp
vaccin
circul
strain
influenza
viru
fulllength
code
region
np
gene
viru
control
murin
cmv
promot
polya
similarli
insert
region
genom
gene
hadhanp
orient
recombin
viru
plaqu
purifi
genom
analyz
restrict
enzym
digest
confirm
presenc
ha
np
gene
cassett
absenc
major
delet
insert
cell
mockinfect
infect
empti
vector
hadhanp
multipl
infect
moi
pfu
per
cell
cell
harvest
h
postinfect
cell
lysat
prepar
analyz
western
blot
polyclon
serum
ha
obtain
immunolog
pathogenesi
branch
influenza
divis
center
diseas
control
prevent
atlanta
ga
usa
monoclon
antibodi
np
obtain
immunolog
pathogenesi
branch
influenza
divis
center
diseas
control
prevent
atlanta
ga
usa
confirm
express
ha
np
protein
mock
pb
serv
neg
control
week
old
femal
balbc
mice
animalsgroup
inocul
either
im
rout
singl
dose
pfu
hadwt
group
refer
hadprim
group
unprim
mice
similarli
inocul
phosphatebuff
salin
pb
four
week
prime
mice
bled
retroorbit
punctur
evalu
develop
hadspecif
neutral
antibodi
titer
hadprim
pbsinocul
mice
subsequ
immun
twice
week
apart
pfu
hadhanp
vaccin
either
im
rout
addit
group
hadprim
mice
similarli
immun
pfu
vector
control
serv
neg
control
four
week
final
immun
blood
sampl
collect
retroorbit
punctur
evalu
develop
haspecif
antibodi
five
anim
group
euthan
collect
spleen
cell
evalu
induct
ha
npspecif
cmi
respons
remain
mice
group
challeng
mous
infecti
dose
revers
genet
deriv
apuerto
contain
ha
na
gene
fragment
sinc
reassort
viru
lethal
produc
clinic
diseas
weight
loss
mice
protect
efficaci
monitor
viral
clearanc
lung
three
day
postchalleng
mice
euthan
lung
collect
determin
viral
titer
evalu
protect
efficaci
briefli
thaw
lung
tissu
homogen
ml
steril
pb
lung
homogen
titrat
embryon
egg
dilut
posit
egg
identifi
hemagglutin
hors
red
blood
cell
allanto
fluid
valu
express
sem
limit
viru
detect
set
np
gene
fairli
conserv
ad
vector
backbon
challeng
viru
ident
amino
acid
level
ident
nucleotid
level
one
major
cell
epitop
conserv
neutral
serum
antibodi
titer
determin
previous
describ
viru
neutral
titer
reciproc
highest
serum
dilut
complet
prevent
develop
cpe
prechalleng
serum
sampl
analyz
presenc
hi
antibodi
titer
use
hors
red
blood
cell
describ
previous
splenocyt
isol
stain
murin
mhc
pentam
immunodomin
epitop
proimmun
inc
bradenton
fl
conjug
phycoerythrin
pe
antibodi
conjug
allophycocyanin
apc
bd
pharmingen
san
jose
ca
describ
previous
b
cell
remov
stain
splenocyt
flouroisothiocyanin
fitc
gate
analysi
flow
cytometr
analys
done
use
bd
facscantoii
bd
bioscienc
san
jose
ca
identifi
percent
epitopespecif
cell
among
total
splenic
cell
filter
plate
millipor
bedford
coat
antimous
interferon
gamma
antibodi
bd
bioscienc
san
jose
ca
incub
overnight
splenocyt
cell
per
well
mice
cultur
presenc
peptid
rpmi
medium
gibco
grand
island
ny
supplement
reconstitut
fetal
bovin
serum
h
develop
accord
elispot
protocol
splenocyt
cultur
presenc
phorbol
myrist
acet
pma
ionomycin
sigmaaldrich
inc
st
loui
mo
serv
posit
control
within
group
logtransform
titer
measur
assess
shapirowilktest
found
normal
distribut
use
analysi
use
sa
tukey
multipl
comparison
use
calcul
signific
signific
set
p
